Miller Anestesia

El sistema nervioso autónomo

Sección I

Fisiología y anestesia

9. Struthers AD,Reid JL: The role of adrenal medullary

catecholamines in potassium homoeostasis. Clin Sci

66:377, 1984.

10. Brown M: Hypokalemia from

-receptor stimula-

tion by circulating epinephrine.Am J Cardiol 56:3D,

1985.

11. Vincent HH, ManIn’t Veld AJ, Boomsma F, et al:

Prevention of epinephrine-induced hypokalemia by

nonselective beta blockers. Am J Cardiol 56:10D,

1985.

12. Johns RA: EDRF/nitric oxide: The endogenous

nitrovasodilator and a new cellular messenger.

Anesthesiology 75:927, 1991.

13. Snyder SH, Bredt DS: Biological roles of nitric oxide.

Sci Am 266:68, 1992.

14. Sakurai T, Yanagisawa M, Masaki T: Molecular cha-

racterization of endothelin receptors. Trends Phar-

macol Sci 13:103, 1992.

15. Nava E, Palmer R, Moncada S: Inhibition of nitric

oxide synthesis in septic shock: How much is bene-

ficial? Lancet 338:1555, 1991.

16. Moore K,Wendon J,Frazer M,et al: Plasma endothe-

lin immunoreactivity in liver disease and the hepa-

torenal syndrome. N Engl J Med 327:1774, 1992.

17. Conlay L, Maher TJ, Wurtman RJ: Tyrosine increa-

ses blood pressure in hypotensive rats. Science

212:559, 1981.

18. Nussdorfer GG: Pancrine control of adrenal cortical

function by medullary chromaffin cells. Pharmacol

Rev 48:495, 1996.

19. Livett BG,Marley PD: Effects of opioid peptides and

morphine on histamine-induced catecholamine

secretion from cultured, bovine adrenal chromaffin

cells. Br J Pharmacol 89:327, 1986.

20. Marley PD, Livett BG: Differences between the

mechanism of adrenaline and noradrenaline secre-

tion from isolated, bovine, adrenal chromaffin cells.

Neurosci Lett 77:81, 1987.

21. Owen PJ, Plevin R, Boarder MR: Characterization

of bradykinin-stimulated release of noradrenal

ine from cultured bovine adrenal chromaffin cells.

J Pharmacol Exp Ther 248:1231, 1989.

22. Cahill A, Perlman RL: Phorbol esters cause prefe-

rential secretion of norepinephrine from bovine

chromaffin cells. J Neurochem 58:768, 1992.

23. Pacholczyk T, Blakely RD, Amara SG: Expression

cloning of a cocaine and antidepressant sensitive

human noradrenaline transporter. Nature 350:350,

1991.

24. Eisenhofer G: The role of neuronal and extraneuro-

nal plasma membrane transporters in the inactiva-

tion of peripheral catecholamines. Pharmacol Ther

91:35, 2001.

25. Moss J, Lappas D, Slater E: Role of the rennin cate-

cholamine system in hemodynamic performance in

man.

Usdin E, Kvetnansky R, Kopin IJ (eds):

Catecholamines and Stress: Recent Advances in

Neurosciences. New York, Elsevier, 1980, p 513.

26. Kaye DM, Lambert GW, Lefkovits J, et al: Neuroche-

mical evidence of cardiac sympathetic activation

and increased central nervous system norepine-

phrine turnover in severe congestive heart failure.

J Am Coll Cardiol 23:570, 1994.

27. Cohn J, Levine T, Olivari M, et al: Plasma norepine-

phrine as a guide to prognosis in patients with

chronic congestive heart failure. N Engl J Med

311:819, 1984.

28. Bristow M: The adrenergic nervous system in heart

failure [editorial]. N Engl J Med 311:850, 1984.

29. Eisenhofer G, Friberg P, Rundqvist B, et al: Cardiac

sympathetic nerve function in congestive heart

failure. Circulation 93:1667, 1996.

30. Port JD, Gilbert EM, Larrabee P, et al: Neurotrans-

mitter depletion compromises the ability of indirect-

acting amines to provide inotropic support in the

failing human heart. Circulation 81:929, 1990.

31. Lawhead R, Blaxall H, Bylund D:

is the predo-

minant

-adrenergic receptor subtype in human

spinal cord. Anesthesiology 77:983, 1992.

32. Bylund DB: Subtypes of

and

adrenergic recep-

tors. FASEB J 6:832, 1992.

33. Szabo B, Hedler L, Starke K: Peripheral presynaptic

and central effects of clonidine, yohimbine and

rauwolscine on the sympathetic nervous system in

rabbits. Naunyn Schmiedebergs Arch Pharmacol

340:648, 1989.

34. Ongioco RR, Richardson CD, Rudner XL, et al:

Adrenergic receptors in human dorsal root ganglia:

Predominance of

and

subtype mRNAs.

Anesthesiology 92:968, 2000.

35. Michelotti GA, Price DT, Schwinn DA:

-Adrener-

gic receptor regulation: Basic science and clinical

implications. Pharmacol Ther 88:281, 2000.

36. Small KM,Wagoner LE, Levin AM, et al: Synergistic

polymorphisms of

- and

-adrenergic receptors

and the risk of congestive heart failure. N Engl J

Med 347:1135, 2002.

37. Michel MC, Kenny B, Schwinn DA: Classification of

-adrenoceptor subtypes. Naunyn Schmiedebergs

Arch Pharmacol 352:1, 1995.

38. Boehm S, Kubista H: Fine tuning of sympathetic

transmitter release via ionotropic and metabotropic

presynaptic receptors. Pharmacol Rev 54:43, 2002.

39. Szabo B, Schramm A, Starke K: Effect of yohimbine

on renal sympathetic nerve activity and renal nore-

pinephrine spillover in anesthetized rabbits. J Phar-

macol Exp Ther 260:780, 1992.

40. Limberger N, Singer EA, Starke K: Only activated

but not non-activated presynaptic

-autoreceptors

interfere with neighbouring presynaptic receptor

mechanisms. Naunyn Schmiedebergs Arch Phar-

macol 338:62, 1988.

41. Raymond J, Hnatowich M, Lefkowitz R, et al: Adre-

nergic receptors: Models for regulation of signal

transduction processes. Hypertension 15:119, 1990.

42. Vanhees L, Aubert A, Fagard R, et al: Influence of

- versus

-adrenoceptor blockade on left ventri-

cular function in humans. J Cardiovasc Pharmacol

8:1086, 1986.

43. Opie L: Ventricular overload and heart failure.

Opie LH (ed): The Heart: Physiology and Metabo-

lism, 2nd ed. New York, Raven Press, 1991, p 386.

44. Brodde O: The functional importance of

and

adrenoceptors in the human heart. Am J Cardiol

62:24C, 1988.

45. Walston J, Silver K, Bogardus C, et al: Time of onset

of non–insulin dependent diabetes mellitus and

genetic variation in the

-adrenergic-receptor gene.

N Engl J Med 333:343, 1995.

46. Widen E, Lehto M, Kanninen T, et al: Association of

a polymorphism in the

-adrenergic receptor gene

with features of the insulin resistance syndrome in

Finns. N Engl J Med 333:348, 1995.

47. Clement K, Vaisse C, Manning BSF, et al: Genetic

variation in the

-adrenergic receptor and an

increased capacity to gain weight in patients with

morbid obesity. N Engl J Med 333:352, 1995.

48. Hall IP, Wheatley A, Wilding P, et al: Association of

Glu27

-adrenoceptor polymorphism with lower

airway reactivity in asthmatic subjects. Lancet

345:1213, 1995.

49. Turki J, Pak J, Green SA, et al: Genetic polymor-

phisms of the

-adrenergic receptor in nocturnal

and non-nocturnal asthma: Evidence that Gly 16

correlates with the nocturnal phenotype. J Clin

Invest 95:1635, 1995.

50. Goldberg LI,Rajfer SI: Dopamine

receptors:Applica

tions in clinical cardiology. Circulation 72:245, 1985.

51. Bertorello A, Aperia A: Both DA

and DA

receptor

agonists are necessary to inhibit Na

ATPase

activity in proximal tubules from the rat kidney.

Acta Physiol Scand 132:441, 1988.

52. BertorelloA,AperiaA: Regulation of Na

ATPase

activity in kidney proximal tubules: Involvement of

GTP binding proteins. Am J Physiol 256:F57, 1989.

53. Gesek FA, Schoolwerth AC: Hormonal interactions

with the proximal Na

exchanger. Am J Physiol

258:F514, 1990.

54. Linder ME, Gilman AG: G Proteins. Sci Am 267:56,

1992.

55. Sprang SR: G protein mechanisms: Insights from

structural analysis. Annu Rev Biochem 66:639, 1997.

56. Alousi AA, Jasper JR, Insel PA, et al: Stoichiometry

of receptor G

-adenylate cyclase interactions.FASEB

J 5:2300, 1991.

57. Post SR, Hilal-Dandan R, Urasawa K, et al: Quanti-

fication of signaling components and amplification

in the

-adrenergic receptor–adenylate cyclase

pathway in isolated adult rat ventricular myocytes.

Biochem J 311:75, 1995.

58. Yatani A, Okabe K, Codina J, et al: Heart rate regu-

lation by G proteins acting on the cardiac pace-

maker channel. Science 249:1163, 1990.

59. Blochl-Daum B, Schuller-Petrovic S, Wolzt M, et al:

Primary defect in

-adrenergic responsiveness in

patients with varicose veins. Clin Pharmacol Ther

49:49, 1991.

60. Insel PA: Adrenergic receptors: Evolving concepts

and clinical implications. N Engl J Med 334:580,

1996.

61. Bristow MR, Ginsburg R, Minobe W, et al: Decrea-

sed catecholamine sensitivity and

-adrenergic

receptor density in failing human hearts. N Engl J

Med 307:205, 1982.

62. Menard L, Ferguson SS, Zhang J, et al: Synergistic

regulation of

-adrenergic receptor sequestration:

Intracellular complement of

-adrenergic receptor

kinase and

-arrestin determine kinetics of interna-

lization. Mol Pharmacol 51:800, 1997.

63. Ferguson SS, Barak LS, Zhang J, et al: G-protein–

coupled receptor regulation: Role of G-protein–

coupled receptor kinases and arrestins. Can J

Physiol Pharmacol 74:1095, 1996.

64. Bristow M, Ginsburg R, Umans V, et al:

- and

adrenergic receptor subpopulations in non-failing

and failing human ventricular myocardium: Coupl

ing of both receptor subtypes to muscle contraction

and selective

receptor downregulation in heart

failure. Circ Res 59:297, 1986.

65. Hedberg A, Kemp F Jr, Josephson ME, et al: Co-

existence of

and

-adrenergic receptors in the

human heart: Effects of treatment with receptor

antagonists or calcium entry blockers. J Pharmacol

Exp Ther 234:561, 1985.

66. Dratman M, Crutchfield F,Axelrod J, et al: Localiza-

tion of triiodothyronine in nerve ending fractions

of rat brain. Proc Natl Acad Sci U S A 73:941,

1976.

67. Jonsson M, Gurley D, Dabrowski M, et al: Distinct

pharmacologic properties of neuromuscular bloc-

king agents on human neuronal nicotinic acetylcho-

line receptors: A possible explanation for the

train-of-four fade. Anesthesiology 105:521, 2006.

68. Tassonyi E, Charpantier E, Muller D, et al: The role

of nicotinic acetylcholine receptors in the mecha-

nisms of anesthesia. Brain Res Bull 57:133, 2002.

69. Eglen RM, Hedge SS, Watson N: Muscarinic recep-

tor subtypes and smooth muscle function. Pharma-

col Rev 48:531, 1996.

70. Hosey MM: Diversity of structure, signaling and

regulation within the family of muscarinic choliner-

gic receptors. FASEB J 12:845, 1992.

71. Bartfai T, Iverfeldt K, Fisone G, et al: Regulation of

the release of coexisting neurotransmitters. Annu

Rev Pharmacol Toxicol 28:285, 1988.

72. Von Kügelgen I, Starke K: Noradrenaline-ATP co-

transmission in the sympathetic nervous system.

Trends Pharmacol Sci 12:319, 1991.